Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

BACKGROUND: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. METHODS: Patients with KRAS mut...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Macarulla, T, Cervantes, A, Tabernero, J, Roselló, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B, Jego, V, von Richter, O, Ciardiello, F
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2015
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580393/
https://ncbi.nlm.nih.gov/pubmed/25989270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.144
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller